Home Newsfeeds Baird Maintains Outperform on Axon Enterprise, Raises Price Target to $237

Baird Maintains Outperform on Axon Enterprise, Raises Price Target to $237

Baird analyst William Power maintains Axon Enterprise (NASDAQ:AXON) with a Outperform and raises the price target from $200 to $237.

byBenzinga Newsdesk

March 1, 2023

1 minute read

Baird analyst William Power maintains Axon Enterprise (NASDAQ:AXON) with a Outperform and raises the price target from $200 to $237.

Deciphera Earns Price Target Bump With Encouraging ESMO Presentation

By Vandana Singh

September 12, 1:38 PM

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) announced positive initial data from the single agent dose escalation portion of the Phase 1 study of…

DCPH

Lucid’s Record Deliveries Show How Putting Up A Hell Of A Fight Looks Like

By Upwallstreet

April 10, 10:45 AM

When the EV pioneer and U.S. market leader, Tesla (NASDAQ: TSLA) reported its quarterly decline in deliveries since 2020, hell of concerns broke lose. If Tesla came short of expectations, what can be expected of others and especially, startups who are already operating on thin ice.

LCID

Universal Stainless Q2 EPS $(0.16) Misses $(0.11) Estimate, Sales $52.20M Beat $51.55M Estimate

By Benzinga Newsdesk

July 27, 6:47 AM

Universal Stainless (NASDAQ:USAP) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 45.45 percent decrease over losses of $(0.11) per share

USAP

Canopy Growth, Aurora Cannabis, Cronos Group Leaving US CBD Market: Distressed Asset Opportunity?

By Nicolas Jose Rodriguez

August 25, 12:08 PM

Once bullish on the US hemp-derived CBD market, Canadian cannabis companies like Canopy Growth Corp.

ACB

Baird Maintains Outperform on Axon Enterprise, Raises Price Target to $237

Related Posts

Deciphera Earns Price Target Bump With Encouraging ESMO Presentation

Lucid’s Record Deliveries Show How Putting Up A Hell Of A Fight Looks Like

Universal Stainless Q2 EPS $(0.16) Misses $(0.11) Estimate, Sales $52.20M Beat $51.55M Estimate

Canopy Growth, Aurora Cannabis, Cronos Group Leaving US CBD Market: Distressed Asset Opportunity?